US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ashland

50.48

+0.93001.88%

Post-market: 50.480.00000.00%16:07 EDT

Volume:404.29K

Turnover:20.42M

Market Cap:2.38B

PE:-110.09

High:50.98

Open:49.91

Low:49.73

Close:49.55

Loading ...

Overview Company News Filings

NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting

Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options

Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients

Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design

Kura Oncology, Kyowa Kirin report data on KOMET-007 at ASH meeting

Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

Ashland celebrates solvers, recognizes 100 years of innovation by planting trees to restore local ecosystems and support sustainable sourcing

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition

Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting

Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH

C4 Therapeutics presents cemsidomide Phase 1 data at ASH

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat

bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition

C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader

Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"Tiger Brokers,U.S. stock trading,Hong Kong stock trading,trading U.S. stocks,stock information,stock prices,U.S. stock quotes,U.S. stock trading,Hong Kong stock trading,IPO trading,buying U.S. stocks,global investment","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ASH/news?page=9"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ASH","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","market":"US","secType":"STK","nameCN":"Ashland","latestPrice":50.48,"timestamp":1744920000000,"preClose":49.55,"halted":0,"volume":404291,"hourTrading":{"tag":"盘后","latestPrice":50.48,"preClose":50.48,"latestTime":"16:07 EDT","volume":15308,"amount":772747.84,"timestamp":1744920471689},"delay":0,"floatShares":46615360,"shares":47182862,"eps":-0.458541,"marketStatus":"Market Closed","change":0.93,"latestTime":"04-17 16:00:00 EDT","open":49.91,"high":50.98,"low":49.725,"amount":20420541.548092,"amplitude":0.025328,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.458541,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":49.55,"dividendRate":0.031696,"preHourTrading":{"tag":"盘前","latestPrice":49.55,"preClose":49.55,"latestTime":"08:02 EDT","volume":10,"amount":492.04998,"timestamp":1744891342185},"postHourTrading":{"tag":"盘后","latestPrice":50.48,"preClose":50.48,"latestTime":"16:07 EDT","volume":15308,"amount":772747.84,"timestamp":1744920471689},"volumeRatio":0.672300055897583,"impliedVol":0.5279,"impliedVolPercentile":0.9562},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ASH\",,,,,undefined,":{"symbol":"ASH","floatShares":46615360,"roa":"1.94%","roe":"0.18%","lyrEps":3.448979,"volumeRatio":0.672300055897583,"shares":47182862,"dividePrice":1.6,"high":50.98,"amplitude":0.025328,"preClose":49.55,"low":49.725,"week52Low":45.21,"pbRate":"0.92","psRate":"1.16","week52High":102.5,"institutionHeld":0.8513,"latestPrice":50.48,"eps":-0.458541,"divideRate":0.031696,"volume":404291,"delay":0,"ttmEps":-0.458541,"open":49.91,"prevYearClose":71.46,"prevWeekClose":50.51,"prevMonthClose":59.29,"prevQuarterClose":59.29,"fiveDayClose":48.59,"twentyDayClose":55.87,"sixtyDayClose":70.63,"earningDate":1745942400000,"earningTime":"盘后"},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ASH\",pageSize:20,pageCount:9,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2490722429","title":"NeoGenomics to Present Key Research on Hematologic Malignancies at the 2024 American Society of Hematology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490722429","media":"Business Wire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490722429?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:10","pubTimestamp":1733749800,"startTime":"0","endTime":"0","summary":"The company will showcase new insights into CNS lymphoma, myeloid malignancies, and gene fusions in acute myeloid leukemia. FT. MYERS, Fla., December 09, 2024----NeoGenomics, Inc. , a leading oncology testing services company, will share its latest research on hematologic malignancies and the prognostic effects of microenvironment signatures in primary central nervous system  lymphoma at the 2024 American Society of Hematology  Annual Meeting, booth #2347, in San Diego, December 7-10. The company will also feature its robust hematological oncology solutions, including COMPASS, AML Express, and AML MRD Flow Panel.NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus for physicians to help them diagnose and treat cancer. The Company's Advanced Diagnostic Divi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/sCebwpkc6aCR2qLArgoo3A--~B/aD05ODQ7dz0yMzkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6b46282d923ea922491ac30ad3a4869c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/sCebwpkc6aCR2qLArgoo3A--~B/aD05ODQ7dz0yMzkwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/6b46282d923ea922491ac30ad3a4869c"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/neogenomics-present-key-research-hematologic-131000749.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NEO","ASH","AFG","BK4107","BK4109","BK4117","BK4121","CNS","BK4135","LU0012050646.USD","BK4196","LU0106261612.USD","LU2463526074.USD"],"gpt_icon":0},{"id":"2490422727","title":"Warm autoimmune hemolytic anemia (wAIHA) research presented by Johnson & Johnson highlights profound disease burden and unmet need for targeted treatment options","url":"https://stock-news.laohu8.com/highlight/detail?id=2490422727","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490422727?lang=en_us&edition=fundamental","pubTime":"2024-12-09 21:00","pubTimestamp":1733749200,"startTime":"0","endTime":"0","summary":"Abstracts presented at ASH 2024 provide insight into the patient experience given the unpredictable nature of wAIHA, a rare autoantibody disease, and the uncertainty of current treatment approaches used to manage the condition. There are no FDA-approved therapies indicated for wAIHA, and patients living with this condition need targeted treatment options with a proven safety and efficacy profile. Johnson & Johnson is evaluating nipocalimab for the potential treatment of wAIHA in the Phase 2/3 ENERGY study, which is expected to read out in 2025. SAN DIEGO, Dec. 9, 2024 /PRNewswire/ --Johnson & Johnson  announced today findings from several online abstracts and posters on patients living with warm autoimmune hemolytic anemia , a rare, life-threatening condition where autoantibodies lead to the premature destruction of red blood cells, at the 2024 American Society of Hematology  Annual Meeting. These findings underscore the significant disease burden for the estimated one in 8,000 people ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/ZX6jJmV7ZALxLT9mcKxo.w--~B/aD0zNzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/388c9d27a537cc3a83771c29d6c3a86b"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/warm-autoimmune-hemolytic-anemia-waiha-130000490.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/warm-autoimmune-hemolytic-anemia-waiha-130000490.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0098860793.USD","LU1066051498.USD","SG9999001440.SGD","LU0234572021.USD","JNJ","IE0034235303.USD","LU1894683348.USD","LU0234570918.USD","SG9999002224.SGD","IE00B29SXK94.USD","IE0002270589.USD","IE00BD4GTT62.SGD","IE000M9KFDE8.USD","LU0320765646.SGD","LU1066051811.HKD","ASH","IE00BVYPNW00.USD","LU1929549753.HKD","IE00BMG7P819.SGD","BK4550","LU0289739699.SGD","LU0466842654.USD","LU1674673691.USD","BK4504","LU1244550221.USD","LU1718418525.SGD","IE00BSNM7G36.USD","LU1032466523.USD","BK4592","IE00BZ18W456.USD","LU2133065610.SGD","LU1267930813.SGD","D","BK4566","IE00BJJMRZ35.SGD","LU1778281490.HKD","LU1162221912.USD","LU1506573853.SGD","IE00B2B36J28.USD","LU0345770308.USD","BK4559","IE00BMG7P587.USD","IE00BJT1NW94.SGD","LU1732799900.SGD","IE00B29SXL02.USD","IE00B4R5TH58.HKD","LU2089984988.USD","LU1261432733.SGD","IE00B1BXHZ80.USD"],"gpt_icon":0},{"id":"2490724528","title":"Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2490724528","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490724528?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:50","pubTimestamp":1733748613,"startTime":"0","endTime":"0","summary":"On Sunday, Arcellx, Inc. revealed new data from its Phase 2 pivotal iMMagine-1 study of anitocabtagene autoleucel  in patients with relapsed or refractory multiple myeloma .The data will be presented at the American Society of Hematology  Annual Meeting and Exposition. Anito-cel is partnered with Kite, a Gilead Science Inc’s  company.Also Read: Arcellx’s Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson’s Multiple Myeloma Cell Therapies: Morgan Stanley. At the time of the data cut, 86 patients were evaluable for efficacy based on a follow-up of at least two months after treatment with anito-cel, and 98 patients were evaluable for safety based on a follow-up of at least one month after treatment with anito-cel.Preliminary results from the Phase 2 iMMagine-1 study demonstrate deep and durable responses with a predictable and manageable safety profile in a high-risk fourth-line or higher RRMM population, including triple- and penta-class refractory disease.This","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/lrLqzErYtt67G6m_brZx1A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/2ed13b35f5b8c4f41b3dac9c81d60df9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/lrLqzErYtt67G6m_brZx1A--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Benzinga/2ed13b35f5b8c4f41b3dac9c81d60df9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcellxs-cancer-cell-therapy-shows-125013309.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4566","BK4504","BK4516","BK4139","BK4097","BK4534","BK4583","IE0002270589.USD","ACLX","LU0109394709.USD","LU1668664300.SGD","LU1430594728.SGD","BK4127","LU0006306889.USD","LU1066051498.USD","LU0058720904.USD","LU1720051108.HKD","LU2357305700.SGD","LU2089283258.USD","LU0098860793.USD","LU1363072403.SGD","LU1720051017.SGD","LU0889565916.HKD","BK4550","LU0971096721.USD","IE00BZ1G4Q59.USD","LU2468319806.SGD","BK4109","LU1162221912.USD","IE00B19Z3581.USD","LU0158827948.USD","LU2089284900.SGD","LU1571399168.USD","GILD","OS","IE00BKVL7J92.USD","ASH","LU2028103732.USD","LU0289739699.SGD","LU0158827781.USD","BK4588","LU0320765992.SGD","LU1989772923.USD","IE00B19Z3B42.SGD","LU2271345857.HKD","BK4568","LU0225283273.USD","BK4578","LU2463526074.USD","BK4581"],"gpt_icon":0},{"id":"2490729613","title":"Silence Therapeutics Presents Promising Phase 1 Data in Polycythemia Vera Patients at the American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490729613","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490729613?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:30","pubTimestamp":1733747400,"startTime":"0","endTime":"0","summary":"New divesiran data continue to show substantial reduction in phlebotomy frequency and lowering of hematocrit levels in PV patients. Silence also announces first subject dosed in Phase 2 study of divesiran in PV patients. Company reinforces commitment to prioritize divesiran development as the first-in-class siRNA in PV. \"PV patients could benefit from a novel treatment option that effectively manages their condition without causing serious adverse effects,\" said Marina Kremyanskaya, MD, PhD, Associate Professor of Medicine, Hematology and Medical Oncology, at the Icahn School of Medicine at Mount Sinai. \"In the Phase 1 portion of the SANRECO study, divesiran substantially reduced the need for phlebotomy and lowered hematocrit levels following infrequent dosing in a range of PV patients. I’m particul","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_8aGH4edOUdJYT3xj6nJeA--~B/aD02NTI7dz0xNzU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f0075e31ea137aec0a64067acedfeabe","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_8aGH4edOUdJYT3xj6nJeA--~B/aD02NTI7dz0xNzU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/f0075e31ea137aec0a64067acedfeabe"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/silence-therapeutics-presents-promising-phase-123000754.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SLN","BK4109","BK4139","LU2463526074.USD","ASH","AFG","LENZ","BK4117","BK4107"],"gpt_icon":0},{"id":"2490152773","title":"ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490152773","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490152773?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:30","pubTimestamp":1733747400,"startTime":"0","endTime":"0","summary":"Publication follows oral presentation at the American Society of Hematology  Annual Meeting. Combination in r/r follicular lymphoma shows best ORR of 97% and CR rate of 77% with 12-month PFS of 95%. Additional IIT data also presented at ASH on ZYNLONTA monotherapy in marginal zone lymphomashows ORR of 91% and 70% CR. LAUSANNE, Switzerland, Dec. 9, 2024 /PRNewswire/ --ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today announced updated data from the investigator-initiated Phase 2 clinical trial evaluating ZYNLONTA in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma  were published in the December issue of The Lancet Haematology, following an oral presentation of the data at the recent 66thAmerican Society of Hematology  Annual Meeting and Exposition.The most common treatment-emergent adverse events  were hyperglycemia  follow","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Et0V8U3X6l.Laaek.1Xhrg--~B/aD0yNTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Et0V8U3X6l.Laaek.1Xhrg--~B/aD0yNTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adc-therapeutics-announces-lancet-haematology-123000558.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-announces-lancet-haematology-123000558.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PBD","BK4139","BK4094","ASH","ADCT","BK4211","BK4161","BK4080","BK4505","BK4195","LENZ","CR","LU2463526074.USD","BK4138","BK4109","ADC","AE","BK4585","BK4231","PFS","BK4588","FL"],"gpt_icon":0},{"id":"2490072998","title":"Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design","url":"https://stock-news.laohu8.com/highlight/detail?id=2490072998","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490072998?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:30","pubTimestamp":1733747400,"startTime":"0","endTime":"0","summary":"Preliminary data suggests improved relapse-free survival compared to published groups of acute myeloid leukemia  patients at high risk of relapse post-transplant. Trem-cel + Mylotarg continue to demonstrate engraftment, shielding, and broadened therapeutic window. Company has received supportive feedback from the FDA regarding a registrational clinical trial design. “With additional maturity, we are even more encouraged by this data and the potential of offering AML and MDS patients the opportunity to receive post-transplant maintenance therapy while still maintaining healthy blood count levels,” said Dr. Eyal Attar, Vor Bio’s Chief Medical Officer.The data released today included 25 patients treated with trem-cel of which 15 had received Mylotarg  as of the data cut-off date of November 1, 2024. The data demonstrated:. Preliminary evidence of improved relapse-free survival  compared to published groups of AML patients at high risk of relapse post hematopoietic stem cell transplant 1.B","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Gn4MjkdcaTWUYmFe5i7lDQ--~B/aD01NTk7dz0xNTQ4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/d3fd6a2f6dbb8f6c0f2434584ba7f0e0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vor-bio-provides-clinical-further-123000594.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["VOR","BK4109","BK4139","LU2463526074.USD","ASH"],"gpt_icon":0},{"id":"2490729230","title":"Kura Oncology, Kyowa Kirin report data on KOMET-007 at ASH meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490729230","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490729230?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:24","pubTimestamp":1733747066,"startTime":"0","endTime":"0","summary":"Kura Oncology (KURA) and Kyowa Kirin provided encouraging clinical data from KOMET-007, a Phase 1 dose-escalation trial of ziftomenib, a highly sel...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kura-oncology-kyowa-kirin-report-data-on-komet-007-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kura-oncology-kyowa-kirin-report-data-on-komet-007-at-ash-meeting?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","KURA","BK4109","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2490882726","title":"Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490882726","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490882726?lang=en_us&edition=fundamental","pubTime":"2024-12-09 20:00","pubTimestamp":1733745600,"startTime":"0","endTime":"0","summary":"– Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients aliv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993609/35186/en/Kura-Oncology-and-Kyowa-Kirin-Report-Positive-Combination-Data-for-Ziftomenib-at-American-Society-of-Hematology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AFG","BK4161","BK4505","CR","FTI","KURA","LU0300736062.USD","LU0054578231.USD","LU0300736492.USD","BK4109","LU0053671581.USD","LU2463526074.USD","BK4179","BK4117","BK4107","BK4139","ASH"],"gpt_icon":0},{"id":"2490238437","title":"Ashland celebrates solvers, recognizes 100 years of innovation by planting trees to restore local ecosystems and support sustainable sourcing","url":"https://stock-news.laohu8.com/highlight/detail?id=2490238437","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490238437?lang=en_us&edition=fundamental","pubTime":"2024-12-09 19:30","pubTimestamp":1733743800,"startTime":"0","endTime":"0","summary":"Ashland is celebrating its solvers and 100-years of innovation through a strategic partnership with the Arbor Day Foundation to restore local ecosystems and support sustainable sourcing. Through the collaboration, the Foundation is planting 15,200 native trees in honor of each employee.Ashland has entered into a strategic partnership with the Arbor Day Foundation.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993581/0/en/Ashland-celebrates-solvers-recognizes-100-years-of-innovation-by-planting-trees-to-restore-local-ecosystems-and-support-sustainable-sourcing.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ESG","BK4109","ASH","LU2463526074.USD"],"gpt_icon":0},{"id":"2490713101","title":"Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490713101","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490713101?lang=en_us&edition=fundamental","pubTime":"2024-12-09 14:00","pubTimestamp":1733724000,"startTime":"0","endTime":"0","summary":"Findings reveal promising early signs that lacutamab may help alleviate some of the most distressing symptoms of cutaneous T cell lymphomas. Innate Pharma SA   today announced new data highlighting the quality-of-life improvements observed in patients with cutaneous T-cell lymphoma  treated with lacutamab in the TELLOMAK Phase 2 clinical study. These data were presented at the 66th American Society of Hematology  Annual Meeting in San Diego, California.The TELLOMAK study addresses a critical unmet need for patients with advanced-stage CTCL, particularly Sézary syndrome  and mycosis fungoides , who often experience debilitating symptoms such as severe itching and recurrent skin infections that profoundly impact their physical and social well-being.Patient Profile: Median age of 69, advanced disease , and a median of five prior systemic therapies, high score of pruritus  and severe Skindex-29 score  at","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/S3d2z6.8Hd_WflLKKLjigw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/646921f25dc14927fb658297457f5944","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/S3d2z6.8Hd_WflLKKLjigw--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/646921f25dc14927fb658297457f5944"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innate-pharma-presents-lacutamab-improved-060000716.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ADC","BK4563","IPHYF","LU2463526074.USD","BK4526","BK4539","MF","IPHA","BK4113","BK4139","BK4109","BK4080","BK4231","ASH"],"gpt_icon":0},{"id":"2490794743","title":"Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2490794743","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490794743?lang=en_us&edition=fundamental","pubTime":"2024-12-09 12:00","pubTimestamp":1733716800,"startTime":"0","endTime":"0","summary":"-- Preliminary results from 86 patients enrolled in the Phase 2 pivotal iMMagine-1 study of anito-cel demonstrated 97% ORR and 62% CR/sCR at a median follow-up of 9.5 months --. -- No delayed neurotoxicities have been observed to date with anito-cel, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome in more than 150 patients dosed across the Phase 1 and iMMagine-1 studies --. -- 30.2-month median progression-free survival with a median follow-up of 38.1 months in the Phase 1 study of anito-cel; median overall survival not reached --. No delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Bar","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/CFG8z5HWByP2us2nm79JHQ--~B/aD0xMjMzO3c9NDI0NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/c5bfb71bc06674ba766ed33926515f70","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/CFG8z5HWByP2us2nm79JHQ--~B/aD0xMjMzO3c9NDI0NDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/business-wire.com/c5bfb71bc06674ba766ed33926515f70"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/arcellx-announces-positive-data-immagine-040000047.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","BK4195","IE00B66KJ199.SGD","SOC","BK4006","BK4139","BK4211","CRS","ASH","OS","IE00B7SZL793.SGD","LU2463526074.USD","BK4097","ACLX","PFS","IE00B19Z4B17.USD","BK4213","BK4109"],"gpt_icon":0},{"id":"2490643077","title":"Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490643077","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490643077?lang=en_us&edition=fundamental","pubTime":"2024-12-09 09:00","pubTimestamp":1733706000,"startTime":"0","endTime":"0","summary":"Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated, en","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/09/2993429/0/en/Disc-Medicine-Presents-Positive-Updated-Results-from-Phase-1b-Trial-in-Patients-with-Myelofibrosis-MF-and-Anemia-in-an-Oral-Presentation-at-the-66th-American-Society-of-Hematology-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4117","BK4526","BK4563","BK4539","IRON","BK4139","BK4113","MF","ASH","AFG","LU2463526074.USD","BK4107","BK4138","BK4109","AE"],"gpt_icon":0},{"id":"2490750500","title":"Vertex Pharmaceuticals presents long-term data on CASGEVY at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490750500","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490750500?lang=en_us&edition=fundamental","pubTime":"2024-12-09 05:50","pubTimestamp":1733694620,"startTime":"0","endTime":"0","summary":"Vertex Pharmaceuticals (VRTX) announced longer-term data for CASGEVY from global clinical trials in people with severe sickle cell disease or trans...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-presents-long-term-data-on-casgevy-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-presents-long-term-data-on-casgevy-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ASH","LU0058720904.USD","LU1093756168.USD","LU0417517546.SGD","LU0889565916.HKD","LU0823416689.USD","IE00B894F039.SGD","LU2324357040.USD","LU1430594728.SGD","LU0061475181.USD","BK4532","IE00B2B36J28.USD","LU2462157665.USD","LU1035775433.USD","BK4139","LU1093756325.SGD","LU2362541273.HKD","LU2236285917.USD","LU2362541513.USD","BK4567","IE00B19Z9Z06.USD","LU0234570918.USD","LU0256863811.USD","IE0002141913.USD","IE0002270589.USD","BK4585","LU0109394709.USD","IE00B19Z3581.USD","LU0289739699.SGD","LU1585245621.USD","BK4588","IE00BJT1NW94.SGD","IE00B19Z3B42.SGD","IE00BJJMRZ35.SGD","LU2237438978.USD","LU2362540622.SGD","LU1069344957.HKD","IE0009355771.USD","LU2417539215.USD","LU0079474960.USD","IE00B19Z9P08.USD","IE00BZ9MQY76.HKD","VERX","LU2463526074.USD","BK4023","BK4109","IE00B4R5TH58.HKD","BK4533","LU0320765992.SGD","VRTX"],"gpt_icon":0},{"id":"2490434757","title":"C4 Therapeutics presents cemsidomide Phase 1 data at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490434757","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490434757?lang=en_us&edition=fundamental","pubTime":"2024-12-09 05:25","pubTimestamp":1733693104,"startTime":"0","endTime":"0","summary":"C4 Therapeutics (CCCC) presented clinical data from the ongoing Phase 1 trial of cemsidomide, an orally bioavailable small molecule degrader of IKZ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/c4-therapeutics-presents-cemsidomide-phase-1-data-at-ash?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/c4-therapeutics-presents-cemsidomide-phase-1-data-at-ash?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CCCC","LENZ","BK4109","ASH","LU2463526074.USD","BK4139"],"gpt_icon":0},{"id":"2490975608","title":"Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2490975608","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490975608?lang=en_us&edition=fundamental","pubTime":"2024-12-09 02:45","pubTimestamp":1733683500,"startTime":"0","endTime":"0","summary":"NHP Data Showed CD117 Monoclonal Antibody (mAb) Conditioning Successfully Achieved Long-term Engraftment of Base-edited Hematopoietic Stem Cells and Induced Robust Levels ofHemoglobin F mAb Dosing Wel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/08/2993408/0/en/Beam-Therapeutics-Presents-New-Non-human-Primate-NHP-Data-Demonstrating-Proof-of-concept-for-ESCAPE-a-Non-genotoxic-Antibody-based-Conditioning-Approach-to-Treating-Sickle-Cell-Dis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PACI.U","LENZ","ASH","AFG"],"gpt_icon":0},{"id":"2490875327","title":"Agios Presents Positive Results from Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat","url":"https://stock-news.laohu8.com/highlight/detail?id=2490875327","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490875327?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:40","pubTimestamp":1733679600,"startTime":"0","endTime":"0","summary":"– ENERGIZE-T Study Achieved Primary and All Key Secondary Endpoints in Adult Patients with Transfusion-Dependent Alpha- or Beta-Thalassemia –。– ENERGIZE-T is First Phase 3 Study to Demonstrate Efficacy of an Oral, Disease-Modifying Treatment for Transfusion-Dependent Alpha- and Beta-Thalassemia–。– Company Filed for Regulatory Approval of Mitapivat  for the Treatment of Adult Patients with Non-Transfusion-Dependent and Transfusion-Dependent Alpha- or Beta-Thalassemia in U.S., European Union, Kingdom of Saudi Arabia and United Arab Emirates –。– Live and Webcast Investor Event with Agios Leadership and Medical Experts will be Hosted in San Diego onMonday, December 9at 7:00 a.m. PT –。“Treatment options for patients with transfusion-dependent thalassemia are extremely limited, and transfusions carry serious risks, such as iron overload, infections and immune reactions. There is a significant need for alternative treatments to manage this debilitating disease,” saidMaria Domenica Cappellini,","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/1.n_derrhoYaVfgBcvtg0w--~B/aD0xMzQxO3c9NzUwNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c805cec60d1b895ac7995fe9db60d850","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/1.n_derrhoYaVfgBcvtg0w--~B/aD0xMzQxO3c9NzUwNjthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/c805cec60d1b895ac7995fe9db60d850"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/agios-presents-positive-results-phase-174000609.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BLDYK493.USD","LU2463526074.USD","BK4181","ASH","IE00B64QTZ34.USD","LU2065731478.USD","BK4218","RBC","BK4161","AGIO","PK","BK4109","BK4139"],"gpt_icon":0},{"id":"2490753279","title":"bluebird bio Presents Positive Long-Term Data On LYFGENIA™ (lovotobegligene autotemcel) Gene Therapy for Sickle Cell Disease at 66th American Society of Hematology (ASH) Annual Meeting and Exposition","url":"https://stock-news.laohu8.com/highlight/detail?id=2490753279","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490753279?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:30","pubTimestamp":1733679000,"startTime":"0","endTime":"0","summary":"Stable production of anti-sickling adult hemoglobin  and elimination or significant reduction of vaso-occlusive events sustained through last follow-up for all evaluable patients , underscoring potentially transformative and durable clinical impact. Results from first and only focused analysis of patients with sickle cell disease with a history of overt or silent stroke  show no stroke recurrence through 9 years of follow-up (n=2). Stacy Rifkin-Zenenberg, DO, Hackensack Meridian Health said: \"These data demonstrate that the significant clinical benefits of lovo-cel for people living with sickle cell disease are durable through continued long-term follow-up. Additionally, the number of patients treated, and duration of follow-up, has enabled detailed exploration of the pharmacology and mechanism of action of LVV gene therapy for sickle cell disease, providing even greater support that one-time treatment with lovo-cel has the potential to permanent","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Mond8jjL4OCttTkWax9fMA--~B/aD0zNDg7dz0xMzk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bd0810a5dbdee2dda0aed883a72fb761","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Mond8jjL4OCttTkWax9fMA--~B/aD0zNDg7dz0xMzk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/bd0810a5dbdee2dda0aed883a72fb761"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/bluebird-bio-presents-positive-long-173000102.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4107","BK4578","SCD","BK4556","BLUE","BK4117","BK4139","AFG","BK4109","LU2463526074.USD","ASH"],"gpt_icon":0},{"id":"2490487753","title":"C4 Therapeutics Presents Cemsidomide Phase 1 Data at the American Society for Hematology (ASH) Annual Meeting that Demonstrated Potential to Become Best-in-Class IKZF1/3 Degrader","url":"https://stock-news.laohu8.com/highlight/detail?id=2490487753","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490487753?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:30","pubTimestamp":1733679000,"startTime":"0","endTime":"0","summary":"In Multiple Myeloma, Cemsidomide in Combination with Dexamethasone at Highest Dose Level Explored to Date Achieved 36 Percent Overall Response Rate (ORR) and 45 Percent Clinical Benefit Rate (CBR); Re","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/08/2993401/0/en/C4-Therapeutics-Presents-Cemsidomide-Phase-1-Data-at-the-American-Society-for-Hematology-ASH-Annual-Meeting-that-Demonstrated-Potential-to-Become-Best-in-Class-IKZF1-3-Degrader.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","CCCC","BK4503","AFG","BK4109","ASH","BK4139","BK4166","QD","BK4117","LENZ","LU2463526074.USD","BK4107"],"gpt_icon":0},{"id":"2490226759","title":"Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH","url":"https://stock-news.laohu8.com/highlight/detail?id=2490226759","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490226759?lang=en_us&edition=fundamental","pubTime":"2024-12-09 01:30","pubTimestamp":1733679000,"startTime":"0","endTime":"0","summary":"– RWE Shows Decreasing Trend Over Time of Cytokine Release Syndrome and Related Adverse Events After Yescarta Treatment in Third-Line Plus Setting –。– Findings from ALYCANTE Study Show Stable Long-Term Quality of Life for R/R LBCL Patients Treated with Yescarta –。SANTA MONICA, Calif., December 08, 2024----Kite, a Gilead Company , today announced findings from three new analyses for Yescarta  that demonstrate improved outcomes for people living with relapsed or refractory (R/R) large B-cell lymphoma , which were presented at 66th American Society of Hematology  Annual Meeting & Exposition.Abstract #526Real-World Early Outcomes of Second-Line Axicabtagene Ciloleucel  Therapy in Patients  With Relapsed or Refractory (R/R) Large B-Cell Lymphoma . The largest real-world analysis of 446 patients from 89 U.S. centers from the CIBMTR Registry with LBCL  who received second-line Yescarta treatment demonstrated outcomes consistent with the ZUMA-7 study across broader patient and disease ch","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/7IgvZFOGXb1eU_LS4aLmQA--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7b549b590d72563b418e104a82291999","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/7IgvZFOGXb1eU_LS4aLmQA--~B/aD00ODA7dz0xNTk1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/7b549b590d72563b418e104a82291999"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kite-presents-data-underscoring-curative-173000565.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2087621335.USD","CRS","BK4213","IE00B7SZLL34.SGD","LU0058720904.USD","BK4080","BK4139","IE00B19Z4B17.USD","BK4550","OS","ASH","BK4588","IE00B66KJ199.SGD","IE00BZ1G4Q59.USD","BK4578","GILD","LU0320765992.SGD","LU1585245621.USD","BK4006","BK4585","BK4568","BK4583","BK4211","BK4195","LU0234570918.USD","BK4161","LU1066051498.USD","LU1066053197.SGD","LU2463526074.USD","IE00BKVL7J92.USD","LU0109394709.USD","SOC","IE00B3T34201.USD","KRG","IE00BSNM7G36.USD","BK4097","LU1839511570.USD","BK4532","BK4566","BK4094","BK4109","CR","IE0031619046.USD","LU0289739699.SGD","LU1571399168.USD","IE00B19Z3581.USD","FL","LU2468319806.SGD","PFS","IE0002270589.USD"],"gpt_icon":0},{"id":"2490583487","title":"DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smoldering multiple myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490583487","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490583487?lang=en_us&edition=fundamental","pubTime":"2024-12-09 00:21","pubTimestamp":1733674860,"startTime":"0","endTime":"0","summary":"First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study. SAN DIEGO, Dec. 8, 2024 /PRNewswire/ -- Johnson & Johnson  today announced data fromthe Phase 3 AQUILA study showing that DARZALEX FASPRO  significantly delayed progression from high-risk smoldering multiple myeloma  to active multiple myeloma  and extended overall survival compared to the current standard of care of active monitoring.1The data were presented for the first time as an oral presentation at the 2024 American Society of Hematology  Annual Meeting , as part of the Press Program and were selected for the Best of ASH session.Additionally, patients who received DARZALEX FASPRO saw a higher overall response rate of 63.4 percent compared to 2.0 percent with active monitoring . Median time to first-line MM treatment was not reached for patients receiving DARZALEX FASPRO compared to","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/6_sqnqYDdG6MlUbMNpXtxA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/98a69363438bceaa4d51faba78e29c5c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/6_sqnqYDdG6MlUbMNpXtxA--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/98a69363438bceaa4d51faba78e29c5c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/darzalex-faspro-daratumumab-hyaluronidase-fihj-162100357.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/darzalex-faspro-daratumumab-hyaluronidase-fihj-162100357.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1674673428.USD","IE00BFTCPJ56.SGD","IE000M9KFDE8.USD","LU1585245621.USD","BK4592","LU1935042991.SGD","BK4588","LU0345769631.USD","LU1267930813.SGD","LU1929549753.HKD","LU2347655156.SGD","BK4504","LU1221951129.SGD","LU1244550221.USD","IE0002141913.USD","LU1430594728.SGD","LU1280957306.USD","BK4568","LU0203345920.USD","BK4572","PFS","IE00B19Z3581.USD","BK4211","LU1261432733.SGD","BK4585","BK4109","LU1878469433.USD","LU0466842654.USD","AL","SG9999001440.SGD","IE00BSNM7G36.USD","SPE","LU1059921491.USD","JNJ","IE00B7SZLL34.SGD","IE00BGHQF631.EUR","PI","IE00B42XCP33.USD","BK4141","LU1894683264.USD","LU1674673691.USD","SG9999002232.USD","BK4532","LU1074936037.SGD","LU0889566641.SGD","ASH","LU0289739699.SGD","BK4007","LU1032955483.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":9,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ASH\",params:#limit:5,,,undefined,":[{"date":"2025-04-30","symbol":"ASH","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":1.14,"defaultRemindTime":1746043200000,"name":null,"time":"Post Market","dateTimestamp":1745985600000,"actualEps":null},{"date":"2025-02-28","symbol":"ASH","amount":0.405,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-01","defaultRemindTime":1740753000000,"name":"亚什兰","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-15","payableDate":"2025-03-01","currency":"USD","dateTimestamp":1740718800000,"payDate":"2025-03-15"},{"market":"US","date":"2025-01-28","symbol":"ASH","fiscalQuarterEnding":"2024/12","expectedEps":0.2,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1738040400000,"reportTimeType":"post","actualEps":0.28},{"date":"2024-11-29","symbol":"ASH","amount":0.405,"announcedDate":"2024-11-14","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-01","defaultRemindTime":1732890600000,"name":"亚什兰","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-15","payableDate":"2024-12-01","currency":"USD","dateTimestamp":1732856400000,"payDate":"2024-12-15"},{"market":"US","date":"2024-11-06","symbol":"ASH","fiscalQuarterEnding":"2024/09","expectedEps":1.33,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1730869200000,"reportTimeType":"post","actualEps":1.26}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ASH\",market:\"US\",,,undefined,":[{"executeDate":"2015-05-27","recordDate":"2015-05-29","paymentDate":"2015-06-15","value":0.39,"currency":"USD"},{"executeDate":"2015-08-19","recordDate":"2015-08-21","paymentDate":"2015-09-15","value":0.39,"currency":"USD"},{"executeDate":"2015-11-27","recordDate":"2015-12-01","paymentDate":"2015-12-15","value":0.39,"currency":"USD"},{"executeDate":"2016-02-17","recordDate":"2016-02-19","paymentDate":"2016-03-15","value":0.39,"currency":"USD"},{"executeDate":"2016-06-01","recordDate":"2016-06-03","paymentDate":"2016-06-15","value":0.39,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ASH\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.4545,"hold":0.2727,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4545,"analysts":11,"updateTime":1743048000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ASH\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ASH","date":"2025-04-17","current":-106.268673,"percent":0.042184,"low":-152.607239,"twenty":-10.617545,"median":17.86146,"eighty":27.96106,"high":41.666396,"avg":3.080485,"sd":37.618835,"marketCap":2337910812},"quantilePoints":[{"date":"2020-04-24","current":5.830102,"twenty":10.902122,"median":16.855926,"eighty":45.060758,"marketCap":3410609559},{"date":"2020-05-01","current":6.059763,"twenty":10.78415,"median":16.855926,"eighty":45.060758,"marketCap":3544961429},{"date":"2020-05-08","current":-51.569829,"twenty":10.709199,"median":16.855926,"eighty":45.060758,"marketCap":3764597548},{"date":"2020-05-15","current":-48.919702,"twenty":10.615504,"median":16.855926,"eighty":45.060758,"marketCap":3571138223},{"date":"2020-05-22","current":-52.571909,"twenty":9.138439,"median":16.855926,"eighty":45.060758,"marketCap":3837749355},{"date":"2020-05-29","current":-55.619556,"twenty":9.120788,"median":16.855926,"eighty":45.060758,"marketCap":4060227579},{"date":"2020-06-05","current":-59.636156,"twenty":9.07954,"median":16.855926,"eighty":45.060758,"marketCap":4353439368},{"date":"2020-06-12","current":-55.13922,"twenty":9.032533,"median":16.855926,"eighty":45.060758,"marketCap":4025163076},{"date":"2020-06-19","current":-56.936338,"twenty":8.983635,"median":16.855926,"eighty":45.060758,"marketCap":4156352681},{"date":"2020-06-26","current":-55.08953,"twenty":8.930444,"median":16.855926,"eighty":45.060758,"marketCap":4021535714},{"date":"2020-07-02","current":-57.723095,"twenty":8.872607,"median":16.855926,"eighty":45.060758,"marketCap":4213785918},{"date":"2020-07-10","current":-57.093689,"twenty":8.675995,"median":16.855926,"eighty":45.060758,"marketCap":4167839328},{"date":"2020-07-17","current":-63.354616,"twenty":8.557057,"median":16.855926,"eighty":45.060758,"marketCap":4624886983},{"date":"2020-07-24","current":-64.439512,"twenty":8.367293,"median":16.855926,"eighty":45.060758,"marketCap":4704084394},{"date":"2020-07-31","current":-44.748169,"twenty":8.317859,"median":16.855926,"eighty":45.060758,"marketCap":4564313264},{"date":"2020-08-07","current":-47.060277,"twenty":8.104676,"median":16.855926,"eighty":45.060758,"marketCap":4800148210},{"date":"2020-08-14","current":-45.655227,"twenty":7.849302,"median":16.855926,"eighty":45.060758,"marketCap":4656833127},{"date":"2020-08-21","current":-44.599957,"twenty":7.651738,"median":16.855926,"eighty":45.060758,"marketCap":4549195639},{"date":"2020-08-28","current":-44.718527,"twenty":7.25977,"median":16.855926,"eighty":45.060758,"marketCap":4561289739},{"date":"2020-09-04","current":-44.196821,"twenty":6.363575,"median":16.855926,"eighty":45.060758,"marketCap":4508075700},{"date":"2020-09-11","current":-43.260121,"twenty":6.075417,"median":16.855926,"eighty":45.060758,"marketCap":4412532312},{"date":"2020-09-18","current":-42.133709,"twenty":5.834015,"median":16.855926,"eighty":45.060758,"marketCap":4297638363},{"date":"2020-09-25","current":-41.013227,"twenty":5.699102,"median":16.855926,"eighty":45.060758,"marketCap":4183349120},{"date":"2020-10-02","current":-42.044782,"twenty":5.471088,"median":16.855926,"eighty":45.060758,"marketCap":4288567789},{"date":"2020-10-09","current":-44.101965,"twenty":5.216092,"median":16.855926,"eighty":45.060758,"marketCap":4498400420},{"date":"2020-10-16","current":-45.258019,"twenty":4.885092,"median":16.855926,"eighty":45.060758,"marketCap":4616317893},{"date":"2020-10-23","current":-44.754098,"twenty":4.479735,"median":16.855926,"eighty":45.060758,"marketCap":4564917969},{"date":"2020-10-30","current":-41.363007,"twenty":-40.555548,"median":16.855926,"eighty":45.060758,"marketCap":4219026715},{"date":"2020-11-06","current":-44.754098,"twenty":-41.328622,"median":16.855926,"eighty":45.060758,"marketCap":4564917969},{"date":"2020-11-13","current":-9.712181,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4933788013},{"date":"2020-11-20","current":-9.201515,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4674369572},{"date":"2020-11-27","current":-9.108247,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4626989343},{"date":"2020-12-04","current":-8.938913,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4540967808},{"date":"2020-12-11","current":-9.025329,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4584867159},{"date":"2020-12-18","current":-9.373926,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4761954621},{"date":"2020-12-24","current":-9.457494,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4804407095},{"date":"2020-12-31","current":-9.455107,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":4803194167},{"date":"2021-01-08","current":-10.356446,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5261074419},{"date":"2021-01-15","current":-10.145138,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5153730307},{"date":"2021-01-22","current":-10.225125,"twenty":-41.685517,"median":16.855926,"eighty":45.060758,"marketCap":5194363389},{"date":"2021-01-29","current":-9.549419,"twenty":-41.685517,"median":16.84568,"eighty":45.060758,"marketCap":4851104816},{"date":"2021-02-05","current":-10.650636,"twenty":-41.685517,"median":16.798842,"eighty":45.060758,"marketCap":5154907958},{"date":"2021-02-12","current":-10.819853,"twenty":-41.685517,"median":16.763713,"eighty":45.060758,"marketCap":5236808932},{"date":"2021-02-19","current":-10.931411,"twenty":-41.685517,"median":16.727121,"eighty":45.060758,"marketCap":5290802907},{"date":"2021-02-26","current":-10.544092,"twenty":-41.685517,"median":16.708151,"eighty":45.060758,"marketCap":5103340678},{"date":"2021-03-05","current":-10.893807,"twenty":-41.766144,"median":16.655852,"eighty":45.067329,"marketCap":5272602691},{"date":"2021-03-12","current":-11.366361,"twenty":-41.766144,"median":16.626772,"eighty":45.067329,"marketCap":5501318743},{"date":"2021-03-19","current":-11.074305,"twenty":-41.766144,"median":16.605449,"eighty":45.067329,"marketCap":5359963729},{"date":"2021-03-26","current":-11.298674,"twenty":-41.685517,"median":16.565507,"eighty":45.060758,"marketCap":5468558354},{"date":"2021-04-01","current":-11.32625,"twenty":-41.685517,"median":16.544159,"eighty":45.032615,"marketCap":5481905179},{"date":"2021-04-09","current":-11.130711,"twenty":-41.766144,"median":16.513421,"eighty":45.025182,"marketCap":5387264054},{"date":"2021-04-16","current":-11.373882,"twenty":-41.766144,"median":16.49824,"eighty":44.88663,"marketCap":5504958787},{"date":"2021-04-23","current":-11.615799,"twenty":-41.766144,"median":16.458163,"eighty":44.798223,"marketCap":5622046845},{"date":"2021-04-30","current":37.652621,"twenty":-41.766144,"median":16.458163,"eighty":44.763306,"marketCap":5233714269},{"date":"2021-05-07","current":38.556703,"twenty":-41.766144,"median":16.48927,"eighty":44.763306,"marketCap":5359381692},{"date":"2021-05-14","current":38.897371,"twenty":-41.766144,"median":16.508117,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-21","current":38.897371,"twenty":-41.766144,"median":16.532217,"eighty":44.763306,"marketCap":5406734634},{"date":"2021-05-28","current":41.421813,"twenty":-41.766144,"median":16.539302,"eighty":44.763306,"marketCap":5757632076},{"date":"2021-06-04","current":41.177231,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5723635092},{"date":"2021-06-11","current":40.923913,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5688423930},{"date":"2021-06-18","current":38.067538,"twenty":-41.766144,"median":16.551203,"eighty":44.763306,"marketCap":5291387724},{"date":"2021-06-25","current":38.72267,"twenty":-41.766144,"median":16.559996,"eighty":44.763306,"marketCap":5382451074},{"date":"2021-07-02","current":38.32959,"twenty":-41.766144,"median":16.589527,"eighty":44.763306,"marketCap":5327813064},{"date":"2021-07-09","current":38.399471,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5337526488},{"date":"2021-07-16","current":37.713766,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5242213515},{"date":"2021-07-23","current":38.233504,"twenty":-41.766144,"median":16.609898,"eighty":44.763306,"marketCap":5314457106},{"date":"2021-07-30","current":28.544675,"twenty":-41.766144,"median":16.63409,"eighty":44.763306,"marketCap":5166586254},{"date":"2021-08-06","current":28.329928,"twenty":-41.766144,"median":16.642592,"eighty":44.763306,"marketCap":5127716909},{"date":"2021-08-13","current":29.118455,"twenty":-41.766144,"median":16.707431,"eighty":44.763306,"marketCap":5270440286},{"date":"2021-08-20","current":28.051427,"twenty":-41.766144,"median":16.798988,"eighty":44.763306,"marketCap":5077308227},{"date":"2021-08-27","current":29.259383,"twenty":-41.766144,"median":16.876011,"eighty":44.763306,"marketCap":5295948294},{"date":"2021-09-03","current":31.51759,"twenty":-41.685517,"median":16.928602,"eighty":44.762757,"marketCap":5704683753},{"date":"2021-09-10","current":31.051184,"twenty":-41.685517,"median":16.94157,"eighty":44.762757,"marketCap":5620264394},{"date":"2021-09-17","current":30.272724,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5479363017},{"date":"2021-09-24","current":31.121649,"twenty":-41.685517,"median":16.987677,"eighty":44.762757,"marketCap":5633018398},{"date":"2021-10-01","current":30.59149,"twenty":-41.685517,"median":19.684212,"eighty":44.762757,"marketCap":5537059701},{"date":"2021-10-08","current":31.071317,"twenty":-41.685517,"median":19.787677,"eighty":44.762757,"marketCap":5623908395},{"date":"2021-10-15","current":32.124923,"twenty":-41.685517,"median":19.83941,"eighty":44.762757,"marketCap":5814611120},{"date":"2021-10-22","current":32.826209,"twenty":-41.685517,"median":19.917009,"eighty":44.762757,"marketCap":5941543826},{"date":"2021-10-29","current":32.21552,"twenty":-41.604889,"median":19.999764,"eighty":44.762207,"marketCap":5831009125},{"date":"2021-11-05","current":32.916806,"twenty":-41.604889,"median":20.15896,"eighty":44.762207,"marketCap":5957941831},{"date":"2021-11-12","current":29.342491,"twenty":-41.604889,"median":20.28364,"eighty":44.762207,"marketCap":6455347984},{"date":"2021-11-19","current":30.162391,"twenty":-41.604889,"median":20.500749,"eighty":44.762207,"marketCap":6635726039},{"date":"2021-11-26","current":26.923508,"twenty":-41.604889,"median":20.528215,"eighty":44.762207,"marketCap":5923171764},{"date":"2021-12-03","current":26.411959,"twenty":-41.604889,"median":20.552965,"eighty":44.762207,"marketCap":5810630932},{"date":"2021-12-10","current":27.165993,"twenty":-41.604889,"median":20.676932,"eighty":44.762207,"marketCap":5976518382},{"date":"2021-12-17","current":26.837476,"twenty":-41.604889,"median":20.708356,"eighty":44.762207,"marketCap":5904244736},{"date":"2021-12-23","current":26.982334,"twenty":-41.604889,"median":20.728755,"eighty":44.762207,"marketCap":5936113430},{"date":"2021-12-31","current":27.848893,"twenty":-41.604889,"median":20.764302,"eighty":44.762207,"marketCap":6126756513},{"date":"2022-01-07","current":26.876277,"twenty":-41.524262,"median":20.796751,"eighty":44.761658,"marketCap":5912780993},{"date":"2022-01-14","current":27.341891,"twenty":-41.524262,"median":20.868148,"eighty":44.761658,"marketCap":6015216083},{"date":"2022-01-21","current":25.013821,"twenty":-41.524262,"median":20.917445,"eighty":44.761658,"marketCap":5503040636},{"date":"2022-01-28","current":24.677544,"twenty":-41.524262,"median":20.980342,"eighty":44.761658,"marketCap":5429059738},{"date":"2022-02-04","current":25.572734,"twenty":-41.443634,"median":21.023702,"eighty":44.761108,"marketCap":5421419569},{"date":"2022-02-11","current":25.553938,"twenty":-41.443634,"median":21.065338,"eighty":44.761108,"marketCap":5417434905},{"date":"2022-02-18","current":25.494866,"twenty":-41.443634,"median":21.115412,"eighty":44.761108,"marketCap":5404911676},{"date":"2022-02-25","current":25.29617,"twenty":-41.443634,"median":21.157984,"eighty":44.761108,"marketCap":5362788089},{"date":"2022-03-04","current":23.572347,"twenty":-41.443634,"median":21.240692,"eighty":44.761108,"marketCap":4997337504},{"date":"2022-03-11","current":23.66901,"twenty":-41.443634,"median":21.332705,"eighty":44.761108,"marketCap":5017830061},{"date":"2022-03-18","current":25.352557,"twenty":-41.443634,"median":21.402701,"eighty":44.761108,"marketCap":5374742080},{"date":"2022-03-25","current":26.448071,"twenty":-41.443634,"median":21.507199,"eighty":44.761108,"marketCap":5606991049},{"date":"2022-04-01","current":26.544734,"twenty":-41.443634,"median":21.611248,"eighty":44.761108,"marketCap":5627483605},{"date":"2022-04-08","current":26.703154,"twenty":-41.443634,"median":21.681627,"eighty":44.761108,"marketCap":5661068628},{"date":"2022-04-14","current":28.520955,"twenty":-41.443634,"median":21.86021,"eighty":44.761108,"marketCap":6046442530},{"date":"2022-04-22","current":27.734226,"twenty":-41.443634,"median":22.114023,"eighty":44.761108,"marketCap":5879655893},{"date":"2022-04-29","current":5.98168,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5724467780},{"date":"2022-05-06","current":5.79477,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5545595204},{"date":"2022-05-13","current":5.627805,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5385809640},{"date":"2022-05-20","current":5.695617,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5450705483},{"date":"2022-05-27","current":6.155649,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5890955748},{"date":"2022-06-03","current":6.053281,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5792989652},{"date":"2022-06-10","current":5.809521,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5559711268},{"date":"2022-06-17","current":5.398352,"twenty":-41.443634,"median":22.157672,"eighty":44.761108,"marketCap":5166223136},{"date":"2022-06-24","current":5.835537,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5584608729},{"date":"2022-07-01","current":5.86325,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5611129938},{"date":"2022-07-08","current":5.737128,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5490431377},{"date":"2022-07-15","current":5.58499,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5344835356},{"date":"2022-07-22","current":5.922634,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5667961098},{"date":"2022-07-29","current":5.951187,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5439385116},{"date":"2022-08-05","current":6.14725,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5618586516},{"date":"2022-08-12","current":6.304219,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5762055916},{"date":"2022-08-19","current":6.275787,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5736069006},{"date":"2022-08-26","current":6.098679,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5574192212},{"date":"2022-09-02","current":5.884253,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5378207598},{"date":"2022-09-09","current":6.054846,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5534129059},{"date":"2022-09-16","current":5.848121,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5345182567},{"date":"2022-09-23","current":5.752755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5258018139},{"date":"2022-09-30","current":5.625403,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5141618438},{"date":"2022-10-07","current":5.617703,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5134580316},{"date":"2022-10-14","current":5.641396,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5156236075},{"date":"2022-10-21","current":5.922755,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5413398206},{"date":"2022-10-28","current":6.27401,"twenty":-41.524262,"median":22.199705,"eighty":44.761658,"marketCap":5734444824},{"date":"2022-11-04","current":5.909724,"twenty":-41.524262,"median":21.695313,"eighty":44.761658,"marketCap":5401487538},{"date":"2022-11-11","current":6.292902,"twenty":-41.524262,"median":21.556282,"eighty":44.761658,"marketCap":5833519919},{"date":"2022-11-18","current":6.534105,"twenty":-41.524262,"median":9.134384,"eighty":44.761658,"marketCap":6057115624},{"date":"2022-11-25","current":6.524573,"twenty":-41.524262,"median":9.120072,"eighty":44.761658,"marketCap":6048278877},{"date":"2022-12-02","current":6.634386,"twenty":-41.524262,"median":9.077138,"eighty":44.761658,"marketCap":6150076230},{"date":"2022-12-09","current":6.425327,"twenty":-41.524262,"median":9.031818,"eighty":44.761658,"marketCap":5956278049},{"date":"2022-12-16","current":6.216944,"twenty":-41.524262,"median":8.981727,"eighty":44.761658,"marketCap":5763107329},{"date":"2022-12-23","current":6.332842,"twenty":-41.524262,"median":8.929251,"eighty":44.761658,"marketCap":5870544977},{"date":"2022-12-30","current":6.29421,"twenty":-41.524262,"median":8.870812,"eighty":44.761658,"marketCap":5834732428},{"date":"2023-01-06","current":6.238017,"twenty":-41.524262,"median":8.723665,"eighty":44.669031,"marketCap":5782641447},{"date":"2023-01-13","current":6.570492,"twenty":-41.524262,"median":8.558011,"eighty":44.528495,"marketCap":6090846415},{"date":"2023-01-20","current":6.436448,"twenty":-41.524262,"median":8.531792,"eighty":44.433823,"marketCap":5966587722},{"date":"2023-01-27","current":6.301234,"twenty":-41.524262,"median":8.3296,"eighty":44.14834,"marketCap":5841243800},{"date":"2023-02-03","current":6.219087,"twenty":-40.702575,"median":8.3296,"eighty":44.14834,"marketCap":5715340826},{"date":"2023-02-10","current":6.142315,"twenty":-11.558641,"median":8.3296,"eighty":44.14834,"marketCap":5644787763},{"date":"2023-02-17","current":6.10452,"twenty":-11.342294,"median":8.3296,"eighty":44.14834,"marketCap":5610053948},{"date":"2023-02-24","current":6.038378,"twenty":-11.297421,"median":8.3296,"eighty":44.14834,"marketCap":5549269770},{"date":"2023-03-03","current":6.122827,"twenty":-11.1811,"median":8.3296,"eighty":44.14834,"marketCap":5626878140},{"date":"2023-03-10","current":5.75019,"twenty":-11.13773,"median":8.3296,"eighty":44.14834,"marketCap":5284424426},{"date":"2023-03-17","current":5.610229,"twenty":-11.066032,"median":8.3296,"eighty":44.14834,"marketCap":5155800765},{"date":"2023-03-24","current":5.809835,"twenty":-10.976285,"median":8.3296,"eighty":44.14834,"marketCap":5339238729},{"date":"2023-03-31","current":6.065544,"twenty":-10.897567,"median":8.324965,"eighty":44.139273,"marketCap":5574234700},{"date":"2023-04-06","current":5.988772,"twenty":-10.820856,"median":8.324965,"eighty":44.139273,"marketCap":5503681637},{"date":"2023-04-14","current":6.134638,"twenty":-10.775982,"median":8.3296,"eighty":44.14834,"marketCap":5637732457},{"date":"2023-04-21","current":6.151764,"twenty":-10.730374,"median":8.3296,"eighty":44.14834,"marketCap":5653471217},{"date":"2023-04-27","current":5.856489,"twenty":-10.606264,"median":8.340928,"eighty":44.166474,"marketCap":5382113282},{"date":"2023-05-05","current":20.861975,"twenty":-10.43882,"median":8.452838,"eighty":44.175541,"marketCap":4693944269},{"date":"2023-05-12","current":20.287633,"twenty":-10.336151,"median":8.558011,"eighty":44.182524,"marketCap":4564717446},{"date":"2023-05-19","current":21.14158,"twenty":-10.102877,"median":8.693871,"eighty":44.189507,"marketCap":4756855455},{"date":"2023-05-26","current":20.227136,"twenty":-9.78508,"median":8.870812,"eighty":44.196491,"marketCap":4551105489},{"date":"2023-06-02","current":19.892072,"twenty":-9.536436,"median":8.929251,"eighty":44.196491,"marketCap":4475716188},{"date":"2023-06-09","current":20.206194,"twenty":-9.454384,"median":8.98113,"eighty":44.203474,"marketCap":4546393658},{"date":"2023-06-16","current":20.073565,"twenty":-9.376314,"median":9.018699,"eighty":44.210457,"marketCap":4516552059},{"date":"2023-06-23","current":19.475569,"twenty":-9.301666,"median":9.056863,"eighty":44.224123,"marketCap":4382003099},{"date":"2023-06-29","current":19.508145,"twenty":-9.246426,"median":9.092642,"eighty":44.237789,"marketCap":4389332615},{"date":"2023-07-05","current":20.315555,"twenty":-9.193781,"median":9.114705,"eighty":44.251456,"marketCap":4570999888},{"date":"2023-07-14","current":20.455165,"twenty":-9.060547,"median":9.163604,"eighty":44.278788,"marketCap":4602412096},{"date":"2023-07-20","current":21.216038,"twenty":-8.93818,"median":19.183552,"eighty":44.278788,"marketCap":4773608633},{"date":"2023-07-28","current":19.591649,"twenty":4.319692,"median":19.750135,"eighty":44.283744,"marketCap":4682404042},{"date":"2023-08-04","current":19.289348,"twenty":4.38581,"median":19.591649,"eighty":44.129229,"marketCap":4610154209},{"date":"2023-08-11","current":19.13927,"twenty":4.38581,"median":19.482306,"eighty":43.956729,"marketCap":4574285498},{"date":"2023-08-18","current":18.466062,"twenty":4.38581,"median":19.154278,"eighty":43.542383,"marketCap":4413388708},{"date":"2023-08-25","current":18.088722,"twenty":4.38581,"median":18.641868,"eighty":43.319191,"marketCap":4323204519},{"date":"2023-08-31","current":18.781226,"twenty":4.38581,"median":18.466062,"eighty":42.973946,"marketCap":4488713001},{"date":"2023-09-08","current":17.87218,"twenty":4.380867,"median":18.294543,"eighty":42.623722,"marketCap":4271451093},{"date":"2023-09-13","current":17.293307,"twenty":4.378395,"median":18.166977,"eighty":42.388429,"marketCap":4133100350},{"date":"2023-09-22","current":18.005107,"twenty":4.319692,"median":17.86146,"eighty":42.077012,"marketCap":4303220523},{"date":"2023-09-29","current":17.479833,"twenty":4.263461,"median":17.50556,"eighty":41.816324,"marketCap":4177680034},{"date":"2023-10-06","current":17.087485,"twenty":4.263461,"median":17.293307,"eighty":41.73771,"marketCap":4083908975},{"date":"2023-10-13","current":16.418565,"twenty":4.263461,"median":16.945983,"eighty":41.577207,"marketCap":3924037005},{"date":"2023-10-20","current":16.294214,"twenty":4.207231,"median":16.495748,"eighty":41.332109,"marketCap":3894317216},{"date":"2023-10-27","current":16.257767,"twenty":-1.056217,"median":16.28671,"eighty":41.192954,"marketCap":3885606243},{"date":"2023-11-03","current":16.332806,"twenty":-6.207204,"median":16.153784,"eighty":40.948113,"marketCap":3903540598},{"date":"2023-11-10","current":15.616718,"twenty":-6.207204,"median":15.881499,"eighty":40.817223,"marketCap":3732395605},{"date":"2023-11-17","current":16.390693,"twenty":-6.207204,"median":15.574911,"eighty":40.340898,"marketCap":3917375673},{"date":"2023-11-24","current":22.827913,"twenty":-6.207204,"median":15.574911,"eighty":39.96161,"marketCap":4063368468},{"date":"2023-12-01","current":23.015098,"twenty":-8.782697,"median":15.533103,"eighty":39.312288,"marketCap":4096687371},{"date":"2023-12-07","current":23.654406,"twenty":-6.207204,"median":15.574911,"eighty":38.926597,"marketCap":4210484243},{"date":"2023-12-15","current":24.893249,"twenty":-8.782697,"median":15.533103,"eighty":38.72267,"marketCap":4430998377},{"date":"2023-12-22","current":24.325418,"twenty":-8.782697,"median":15.533103,"eighty":38.648421,"marketCap":4329924480},{"date":"2023-12-29","current":24.225549,"twenty":-8.789917,"median":12.47951,"eighty":38.641433,"marketCap":4312147664},{"date":"2024-01-05","current":22.661874,"twenty":-8.797137,"median":9.425916,"eighty":38.597758,"marketCap":4033813516},{"date":"2024-01-12","current":23.423737,"twenty":-8.797137,"median":9.425916,"eighty":38.470225,"marketCap":4169425227},{"date":"2024-01-19","current":22.447867,"twenty":-8.804357,"median":9.30281,"eighty":38.332211,"marketCap":3995720339},{"date":"2024-01-26","current":22.718942,"twenty":-8.797137,"median":9.425916,"eighty":38.217781,"marketCap":4043971696},{"date":"2024-02-02","current":28.85349,"twenty":-8.797137,"median":9.425916,"eighty":38.049194,"marketCap":4731972377},{"date":"2024-02-09","current":27.918791,"twenty":-8.797137,"median":9.425916,"eighty":37.903318,"marketCap":4578681720},{"date":"2024-02-16","current":28.325049,"twenty":-8.797137,"median":9.425916,"eighty":37.631656,"marketCap":4645308051},{"date":"2024-02-23","current":28.413632,"twenty":-8.797137,"median":9.425916,"eighty":37.11978,"marketCap":4659835597},{"date":"2024-03-01","current":28.603015,"twenty":-8.789917,"median":12.47951,"eighty":32.879225,"marketCap":4690894489},{"date":"2024-03-08","current":29.339167,"twenty":-8.789917,"median":12.47951,"eighty":32.536971,"marketCap":4811623405},{"date":"2024-03-15","current":29.363604,"twenty":-8.789917,"median":12.47951,"eighty":32.258469,"marketCap":4815631004},{"date":"2024-03-22","current":29.357495,"twenty":-8.789917,"median":12.47951,"eighty":31.941046,"marketCap":4814629104},{"date":"2024-03-28","current":29.81568,"twenty":-8.789917,"median":12.47951,"eighty":31.40619,"marketCap":4889771583},{"date":"2024-04-05","current":29.122292,"twenty":-8.797137,"median":9.425916,"eighty":31.117622,"marketCap":4776055965},{"date":"2024-04-12","current":29.372767,"twenty":-8.797137,"median":9.425916,"eighty":31.051184,"marketCap":4817133853},{"date":"2024-04-19","current":29.168111,"twenty":-8.797137,"median":9.425916,"eighty":30.606254,"marketCap":4783570213},{"date":"2024-04-26","current":29.079528,"twenty":-8.789917,"median":12.47951,"eighty":30.256618,"marketCap":4769042667},{"date":"2024-05-03","current":24.879315,"twenty":-8.789917,"median":12.47951,"eighty":29.945905,"marketCap":4801707860},{"date":"2024-05-10","current":25.416952,"twenty":-8.789917,"median":12.47951,"eighty":29.757033,"marketCap":4905471669},{"date":"2024-05-17","current":25.614345,"twenty":-8.789917,"median":12.47951,"eighty":29.613467,"marketCap":4943568527},{"date":"2024-05-24","current":25.463703,"twenty":-8.789917,"median":12.47951,"eighty":29.5169,"marketCap":4914494609},{"date":"2024-05-31","current":25.87667,"twenty":-8.789917,"median":12.47951,"eighty":29.365437,"marketCap":4994197245},{"date":"2024-06-07","current":26.035104,"twenty":-8.789917,"median":12.47951,"eighty":29.342276,"marketCap":5024774986},{"date":"2024-06-14","current":25.292282,"twenty":-8.797137,"median":9.425916,"eighty":29.274986,"marketCap":4881410496},{"date":"2024-06-21","current":25.066319,"twenty":-8.804357,"median":9.30281,"eighty":29.230424,"marketCap":4837799620},{"date":"2024-06-28","current":24.487127,"twenty":-8.826676,"median":9.172548,"eighty":29.168722,"marketCap":4726015420},{"date":"2024-07-05","current":24.193634,"twenty":-8.826676,"median":9.172548,"eighty":29.132067,"marketCap":4669371408},{"date":"2024-07-12","current":24.601407,"twenty":-8.826676,"median":9.172548,"eighty":29.097856,"marketCap":4748071495},{"date":"2024-07-15","current":24.596212,"twenty":-8.826676,"median":9.172548,"eighty":29.090525,"marketCap":4747068946},{"date":"2024-08-02","current":24.957234,"twenty":-8.929025,"median":9.114705,"eighty":28.735731,"marketCap":4816746093},{"date":"2024-08-09","current":27.237695,"twenty":-8.929025,"median":9.114705,"eighty":28.677936,"marketCap":4058416549},{"date":"2024-08-16","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.593851,"marketCap":4159010197},{"date":"2024-08-23","current":28.407693,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4232746318},{"date":"2024-08-30","current":29.413827,"twenty":-8.929025,"median":9.114705,"eighty":28.535286,"marketCap":4382660153},{"date":"2024-09-06","current":28.273324,"twenty":-8.929025,"median":9.114705,"eighty":28.515633,"marketCap":4212725252},{"date":"2024-09-13","current":27.91282,"twenty":-8.929025,"median":9.114705,"eighty":28.437936,"marketCap":4159010197},{"date":"2024-09-20","current":28.840298,"twenty":-8.929025,"median":9.114705,"eighty":28.414125,"marketCap":4297204384},{"date":"2024-09-27","current":28.584668,"twenty":-8.929025,"median":9.114705,"eighty":28.410315,"marketCap":4259115526},{"date":"2024-10-04","current":27.693241,"twenty":-8.929025,"median":9.114705,"eighty":28.328952,"marketCap":4126292846},{"date":"2024-10-11","current":27.781728,"twenty":-8.929025,"median":9.114705,"eighty":28.174035,"marketCap":4139477450},{"date":"2024-10-18","current":28.768197,"twenty":-8.929025,"median":9.114705,"eighty":28.155826,"marketCap":4286461373},{"date":"2024-10-25","current":27.847274,"twenty":-8.929025,"median":9.114705,"eighty":28.143107,"marketCap":4149243823},{"date":"2024-10-31","current":28.55845,"twenty":-8.929025,"median":9.114705,"eighty":28.102675,"marketCap":4255208977},{"date":"2024-11-08","current":23.317939,"twenty":-8.93818,"median":9.109339,"eighty":27.987673,"marketCap":3940731747},{"date":"2024-11-15","current":22.552233,"twenty":-8.93818,"median":9.109339,"eighty":27.96198,"marketCap":3811327297},{"date":"2024-11-22","current":21.642415,"twenty":-8.93818,"median":9.127228,"eighty":27.96083,"marketCap":3657568070},{"date":"2024-11-29","current":21.759491,"twenty":-8.93818,"median":9.172548,"eighty":27.96083,"marketCap":3677353987},{"date":"2024-12-06","current":21.310698,"twenty":-8.93818,"median":16.14628,"eighty":27.96083,"marketCap":3601507972},{"date":"2024-12-13","current":20.66399,"twenty":-8.93818,"median":16.326374,"eighty":27.96083,"marketCap":3492214336},{"date":"2024-12-20","current":20.056308,"twenty":-8.93818,"median":16.418565,"eighty":27.96083,"marketCap":3389516005},{"date":"2024-12-27","current":20.109271,"twenty":-8.93818,"median":16.564355,"eighty":27.96083,"marketCap":3398466777},{"date":"2025-01-03","current":19.440263,"twenty":-8.93818,"median":16.920255,"eighty":27.96083,"marketCap":3285404395},{"date":"2025-01-10","current":19.6399,"twenty":-8.938327,"median":17.089629,"eighty":27.96106,"marketCap":3319143109},{"date":"2025-01-17","current":19.75157,"twenty":-8.938327,"median":17.49484,"eighty":27.96106,"marketCap":3338015281},{"date":"2025-01-24","current":20.086579,"twenty":-8.938327,"median":17.759622,"eighty":27.96106,"marketCap":3394631794},{"date":"2025-01-31","current":-136.701619,"twenty":-9.032373,"median":17.86146,"eighty":27.96106,"marketCap":3007435623},{"date":"2025-02-07","current":-139.725612,"twenty":-9.144874,"median":17.86146,"eighty":27.96106,"marketCap":3073963459},{"date":"2025-02-14","current":-139.361017,"twenty":-9.245709,"median":17.86146,"eighty":27.96106,"marketCap":3065942372},{"date":"2025-02-21","current":-140.326121,"twenty":-9.301666,"median":17.86146,"eighty":27.96106,"marketCap":3087174660},{"date":"2025-02-28","current":-131.897546,"twenty":-9.377985,"median":17.86146,"eighty":27.96106,"marketCap":2901746013},{"date":"2025-03-07","current":-127.90845,"twenty":-9.455107,"median":17.87218,"eighty":27.96129,"marketCap":2813985889},{"date":"2025-03-14","current":-119.994597,"twenty":-9.579026,"median":17.87218,"eighty":27.96129,"marketCap":2639881128},{"date":"2025-03-21","current":-119.823023,"twenty":-9.954842,"median":17.87218,"eighty":27.96129,"marketCap":2636106499},{"date":"2025-03-28","current":-128.144364,"twenty":-10.210799,"median":17.87218,"eighty":27.96129,"marketCap":2819176004},{"date":"2025-04-04","current":-113.839378,"twenty":-10.377935,"median":17.87218,"eighty":27.96129,"marketCap":2504466314},{"date":"2025-04-11","current":-104.209785,"twenty":-10.499986,"median":17.86146,"eighty":27.96106,"marketCap":2292615264},{"date":"2025-04-17","current":-106.268673,"twenty":-10.617545,"median":17.86146,"eighty":27.96106,"marketCap":2337910812}],"updateTime":1745133353662}}}